
Edgewise Therapeutics (EWTX) Stock Forecast & Price Target
Edgewise Therapeutics (EWTX) Analyst Ratings
Bulls say
Edgewise Therapeutics is poised to disrupt the market for HCM treatment with its promising drug, securing funding for commercialization and an Outperform rating. While the company has sold its muscular dystrophy business, risks and challenges in securing funding and addressing potential side effects remain. The potential to reach a large, untreated patient population in the US makes this a potential lucrative investment.
Bears say
Edgewise Therapeutics is facing a negative outlook due to several fundamental reasons. The development and potential approval of its product candidates, including Sevasemten and EDG-7500, face challenges such as dose-limiting effects on heart function, which could require additional monitoring and potentially restrict the drug's use. Additionally, the company's financials may also be impacted by the need for further clinical trials and the potential for regulatory approval delays. Furthermore, while the company's drugs target a large market, they face competition from already approved treatments and future entrants in the muscular dystrophy and cardiac disease space.
This aggregate rating is based on analysts' research of Edgewise Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Edgewise Therapeutics (EWTX) Analyst Forecast & Price Prediction
Start investing in Edgewise Therapeutics (EWTX)
Order type
Buy in
Order amount
Est. shares
0 shares